NASDAQ : TELA
TELA Bio, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 0.8101 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 36.57M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 36.57M |
| Enterprise Value | 64.06M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 45.14M |
| Shares Outstanding | 45.14M |
| Shares Change (YoY) | +36.23% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 8.54% |
| Owned by Institutions (%) | 21.16% |
| Float | 21.33M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.46 |
| Forward PS | 0.44 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.99 |
| Quick Ratio | 2.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.88 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.40% |
| Return on Invested Capital (ROIC) | -45.05% |
| Return on Capital Employed (ROCE) | -81.91% |
| Weighted Average Cost of Capital (WACC) | 10.37% |
| Revenue Per Employee | $366,550 |
| Profits Per Employee | -$188,894 |
| Employee Count | 218 |
| Asset Turnover | 1.26 |
| Inventory Turnover | 2.26 |
Taxes
| Measure | Value |
|---|
| Income Tax | 265,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -38.63% |
| 50-Day Moving Average | 1.01 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 33.47 |
| Average Volume (20 Days) | 129,641 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 638,950 |
| Short Previous Month | 469,145 |
| Short % of Shares Out | 1.42% |
| Short % of Float | 3.00% |
| Short Ratio (days to cover) | 2.85 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 79.91M |
| Gross Profit | 54.57M |
| Operating Income | -34.01M |
| Pretax Income | -40.91M |
| Net Income | -41.18M |
| EBITDA | -33.01M |
| EBIT | -34.01M |
| Loss Per Share | -$0.78 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 30.42M |
| Total Debt | 57.92M |
| Net Cash | -27.49M |
| Net Cash Per Share | -$0.61 |
| Equity (Book Value) | -15.87M |
| Book Value Per Share | -0.35 |
| Working Capital | 36.27M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -31.14M |
| Capital Expenditures | -480,000 |
| Depreciation & Amortization | 1.00M |
| Net Borrowing | 17.58M |
| Free Cash Flow | -31.62M |
| FCF Per Share | -$0.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | 68.29% |
| Operating Margin | -42.56% |
| Pretax Margin | -51.20% |
| Profit Margin | -51.53% |
| EBITDA Margin | -41.31% |
| EBIT Margin | -42.56% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.23% |
| Shareholder Yield | -36.23% |
| Earnings Yield | -95.99% |
| FCF Yield | -86.46% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1.90 |
| Price Target Difference | 134.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 6.20% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -9.29 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |